Miejsce:
Online
Data:
06.10 - 08.10 / 2022

15th International Cardiovascular Reasearch Meeting

Konferencja pod patronatem Oddziału Bydgoskiego Polskiego Towarzystwa Kardiologicznego

Transmisja Live

Szanowni Państwo!

Dziękujemy za obecność.

Do zobaczenia!

PROGRAM MERYTORYCZNY

Zapraszamy do zapoznania się ze szczegółami programu.

09:00 - 09:05
Opening speech

Jacek Kubica (PL)

09:05 - 09:25
Opening Lecture - How to optimise antithrombotic therapy in cardiogenic shock?

Diana A. Gorog (UK)

09:25 - 09:30
Break
09:30 - 11:30
SESSION 1
09:30 - 09:45
Predictors of in-hospital clinical outcome in COVID-19 patients

Leszek Gromadziński (PL)

09:45 - 10:00
Determinants of anti-SARS-CoV-2 antibodies after vaccination

Magdalena Krintus (PL)

10:00 - 10:15
Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized non-intesive-care COVID-19 pa-tients - SIRIO randomized study

Przemysław Podhajski (PL)

10:15 - 10:30
Metformin use in patients hospitalized with COVID-19

Paul A. Gurbel (USA)

10:30 - 10:45
IMPACT of PCSK9 inhibition on clinical outcome in patients with COVID-19 (The IMPACT COVID 19 - SIRIO 5 randomized study)

Eliano P. Navarese (IT)

10:45 - 11:00
Post-COVID-19 rehabilitation

Małgorzata Ostrowska (PL)

11:00 - 11:30
DISCUSSION
11:30 - 11:45
Break
11:45 - 13:45
SESSION 2
11:45 - 12:00
NSTE-ACS ESC Guidelines do not recommend pretreatment with P2Y12 Inhibitor

Piotr Niezgoda (PL)

12:00 - 12:05
NSTE-ACS ESC Guidelines do not recommend pretreatment with P2Y12 Inhibitor. A Contrarian View

Wiktor Kuliczkowski (PL)

12:15 - 12:30
NSTE-ACS ESC Guidelines recommend prasugrel as the preferred P2Y12 Inhibitor

Piotr Adamski (PL)

12:30 - 12:45
NSTE-ACS ESC Guidelines recommend prasugrel as the preferred P2Y12 Inhibitor. A Contrarian View

Michael Savage (USA)

12:45 - 13:00
Dual antiplatelet therapy in acute coronary syndrome – a comparison of clopidogrel, prasugrel and ticagrelor – a Metaanalysis

Eliano P. Navarese (IT)

13:00 - 13:15
Dual antiplatelet therapy in acute coronary syndrome – a comparison of clopidogrel, prasugrel and ticagrelor – the PL- ACS Registry

Jacek Kubica (PL)

13:15 - 13:45
DISCUSSION
13:45 - 14:00
Break
14:00 - 16:00
SESSION 3
14:00 - 14:15
Use of ultra-thin strut sirolimus-eluting coronary stents in acute coronary syndrome – is it a way to reduce risk of throbosis?

Tommaso Gori (D)

14:15 - 14:30
Microcirculation assessment in patients with acute coronary syndrome undergoing PCI

Jacek Legutko (PL)

14:30 - 14:45
Pharmacodynamics of cangrelor in cardiogenic shock – clinical implications

Jolanta Siller-Matula (A)

14:45 - 15:00
Is personalized pharmacotherapeutic approach closed for acute coronary syndrome?

Udaya Tantry (USA)

15:00 - 15:15
Prasugrel or ticagrelor in acute coronary syndrome – is a tailored choice justified? – the PL-ACS registry

Jacek Kubica (PL)

15:15 - 15:30
Diurnal variability of platelet aggregation in patients with myocardial infarction treated with prasugrel and ticagrelor

Piotr Adamski (PL)

15:30 - 16:00
DISCUSSION
16:00 - 16:15
Break
16:15 - 18:00
SESSION 4 - Young Researchers Session: COVID-19 - a Challenge for the Healthcare System
  • Vaccination against COVID-19 - does it affect the course of the disease and the severity of symptoms?
    Zuzanna Głowacka
  • Views of the academic community on actively combating the threat of COVID-19
    Bartosz Majchrzak
  • Are facts enough? Convincing the academic community to methods of fighting COVID-19
    Mikołaj Woźnica
  • Can the COVID-19 vaccine save somebody's life?
    Piotr Kolterman
  • The prevalence of the post-COVID syndrome and the assessment of functioning in chronic illness
    Aleksandra Białczyk
  • COVID-19 facts and myths - verification of the public's knowledge about COVID-19 disease
    Dale Verghese
  • The impact of COVID-19 pandemic on mortality of hospitalized patients without COVID-19
    Patryk Rogaczewski
  • Comparison of the angiographic image of the heart in patients with acute coronary syndrome with vs. without COVID-19
    Karolina Skonieczna

09:00 - 09:20
The role of ACE-inhibitors in cardiovascular continuum: focus on the SMILE project

Claudio Borghi (IT)

09:20 - 09:30
Break
09:30 - 11:30
SESSION 5
09:30 - 09:45
Impact of COVID-19 pandemic on out-of- hospital cardiac arrest occurence (OSCAR-POL registry)

Jakub Ratajczak (PL)

09:45 - 10:00
Epidemiology, management and survival rate of out-of-hospital cardiac arrest

Klaudiusz Nadolny (PL)

10:00 - 10:15
Imapct of therapeutic hypothermia after a sudden cardiac arrest in patients with myocardial infarction

Agata Sobczyk (PL)

10:15 - 10:30
Effectiveness of ticagrelor in comatose survivors of out-of-hospital cardiac arrest undergoing PCI and therapeutic hypothermia

Marek T. Tomala (PL)

10:30 - 10:45
Effectiveness of ticagrelor in comatose survivors of out-of-hospital cardiac arrest undergoing PCI and therapeutic hypothermia (UNICORN study)

Julia M. Umińska (PL)

10:45 - 11:00
Stent thrombosis in comatose survivors of out-of-hospital cardiac arrest undergoing PCI and therapeutic hypothermia (ST-OHCA study)

Martin Rauber (SLO)

11:00 - 11:30
DISCUSSION
11:30 - 11:45
Break
11:45 - 13:45
SESSION 6
11:45 - 12:00
Recombinant Human Lecithin Cholesterol Acyl transferase in Acute ST-Elevation Myocardial Infarction: Results of REAL-TIMI 63B

Marc Bonaca (USA)

12:00 - 12:15
Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention in patients with prior CABG (The TWILIGHT-CABG study)

Robert Gil (PL)

12:15 - 12:30
Low-dose prasugrel or clopidogrel for elderly patients with acute coronary syndrome? (A sub-study of the ELDERLY ACS 2 trial)

Stefano De Servi (IT)

12:30 - 12:45
Revascularization in STEMI patients with multi-vessel disease (multicenter registry)

Wojciech Wojakowski (PL)

12:45 - 13:00
Efficacy and Safety of the Oral Factor XIa Inhibitor. Asundexian, Added to Dual Antiplatelet Therapy After an Acute Myocardial Infarction. Main Results of PACIFIC-AMI TRIAL

Andrzej Budaj (PL)

13:00 - 13:15
PCI versus CABG for treatind in-stent restenosis in unprotected left main (LM-DRAGON registry)

Wojciech Wańha (PL)

13:15 - 13:45
DISCUSSION
13:45 - 14:00
Break
14:00 - 16:05
SESSION 7
14:00 - 14:15
Virtual reality-enhanced rehabilitation in patients with coronary artery disease

Robert Gajda (PL)

14:15 - 14:30
Early standardized clinical judgement for syncope diagnosis in the emergency department

Salvatore di Somma (IT)

14:30 - 14:45
Efficacy and safety of CSK9 inhibitors in patients with familial hypercholesterolemia – an observational study

Krzysztof Chlebus (PL)

14:45 - 15:00
Management and predictors of clinical events in 75 686 patients with acute myocardial infarction

Piotr Jankowski (PL)

15:00 - 15:15
The role of miRNAs in regulation of platelet activity

Marek Postuła (PL)

15:15 - 15:30
Impact of levosimendan on clinical outcome in patients with takotsubo syndrome

Miłosz Jaguszewski (PL)

15:30 - 16:00
DISCUSSION
16:00 - 16:05
Closing remarks

Jacek Kubica (PL)

16:05 - 16:15
Break
16:15 - 18:00
SESSION 8 - ELECTRA-SIRIO 2 trial investigators meeting
09:00 - 13:00
ELECTRA-SIRIO 2 trial investigators meeting

Pliki do pobrania

Certyfikat INFARMA

SPONSORZY KONFERENCJI

Kontakt

Kontakt w sprawie
Problemów Technicznych
Krzysztof Sęk

Organizatorem konferencji jest
Katedra Kardiologii i Chorób Wewnętrznych CM UMK
i Katedra Rehabilitacji Kardiologicznej i Promocji Zdrowia CM UMK


Organizatorem logistycznym konferencji jest Grupa Gran
ul. Generała Tadeusza Bora-Komorowskiego 35, 85-793 Bydgoszcz